Meeting
2020 ASCO Virtual Scientific Program
Quilt-3.064: An open-label phase I study of PD-L1 t-haNK in subjects with locally advanced or metastatic solid cancers.
Authors
Tara Elisabeth Seery
Chan Soon Shiong Institute for Medicine, El Segundo, CA
Tara Elisabeth Seery , Mira Kistler , John H. Lee , Patrick Soon-Shiong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT04050709
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3152)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3152
Abstract #
TPS3152
Poster Bd #
216
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.
First Author: Anthony W. Tolcher
Poster
2015 ASCO Annual Meeting
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.
First Author: Karen Kelly
First Author: Igor Tsaur
Poster
2023 ASCO Annual Meeting
Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.
First Author: Raffit Hassan